High-risk and refractory neuroblastomas carry poor overall survival, novel approaches must be explored to improve global outcome. With better knowledge of underlying molecular patterns growing radioligand portfolio, nuclear medicine physicians can test new strategies for disease assessment therapy. For decades, meta-iodobenzylguanidine (mIBG) has been used evaluate extent when coupled with iodi...